This study is testing a new vaccine called RSVpreF to help prevent a lung infection in adults called lower respiratory tract infection (LRTI) caused by the respiratory syncytial virus (RSV). The study is in its third phase, which means it's getting closer to being approved if it works well and is safe. People who are 60 years or older can join. The vaccine is given in one single dose of 120 micrograms (µg), and the study will last about two years for each person. They will check if the vaccine is safe and helps the body make antibodies, which are proteins that fight viruses.
There are three smaller studies within this main study:
- Substudy A - Participants get a second dose of the vaccine after about two years.
- Substudy B - Participants get a second dose after about one year.
- Substudy C - Participants get a second dose after three or four years.
Key Points:
- Study duration: 18-24 months per participant.
- Locations: Conducted in the US, Canada, Netherlands, Finland, Argentina, Japan, and South Africa.
- Participants: Healthy adults 60 years or older, with no severe allergies or unstable health conditions.
How understandable was the trial content above?
Hard to understand
Easy to understand